Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to 98.56%.

  • Maravai Lifesciences Holdings' EBITDA Margin rose 1413700.0% to 98.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.9%, marking a year-over-year decrease of 268100.0%. This contributed to the annual value of 90.91% for FY2024, which is 799500.0% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its EBITDA Margin stood at 98.56% for Q3 2025, which was up 1413700.0% from 139.84% recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year EBITDA Margin high stood at 75.87% for Q3 2021, and its period low was 239.93% during Q3 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 9.64% (2023), whereas its average is 11.16%.
  • In the last 5 years, Maravai Lifesciences Holdings' EBITDA Margin plummeted by -2168800bps in 2024 and then surged by 1413700bps in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBITDA Margin (Quarter) stood at 67.65% in 2021, then dropped by -21bps to 53.37% in 2022, then plummeted by -118bps to 9.64% in 2023, then plummeted by -591bps to 66.66% in 2024, then tumbled by -48bps to 98.56% in 2025.
  • Its EBITDA Margin stands at 98.56% for Q3 2025, versus 139.84% for Q2 2025 and 104.93% for Q1 2025.